灯盏花注射液治疗脑梗死随机对照试验的系统评价

Systematic review of Brevsicapus Injection for cerbral infarction by randomized controlled trail

目的:系统评价灯盏花制剂治疗脑梗死的疗效及安全性。方法:搜集灯盏花治疗脑梗死随机对照试验的文献,筛选合格研究,应用Jadad评分法进行质量评价,运用异质性检验、Meta-分析、漏斗图分析、敏感度分析等方法统计相关数据。结果:19项符合纳入标准,Jadad评分显示所有研究得分均低于3分,属低质量文献。Meta-分析结果显示,总有效率比较的合并OR=3.61,95%CI为(2.93,4.44)。结论:Meta-分析结果提示灯盏花制剂有改善脑梗死患者全血流变指标及微循环、增加脑血流量、且其安全范围大,临床应用不良反应小。由于灯盏花治疗脑梗死随机对照试验的方法学质量较低,存在潜在的临床异质性及发表性偏倚,以及待评价研究等因素的影响,降低了上述结论的可靠性,因此本系统评价尚不能肯定证明灯盏花制剂对于脑梗死的疗效及安全性。

Objective：To evaluate efficacy and safety of Brevsicapus Injection for cerebral infarction by randomized controlled trail.Methods：Randomized controlled trails（RCTs） of Brevsicapus Injection for cerebral infarction were identified,eligible studies were included,the methodological quality of inclusive trails was assissed by Jadad scale hieterogeneity test,Meta-analysis,funnel plot analysis and sensitivity analysis were used to analyse deta.Results：19 RCTs were included,with all trails of low methodological quality.Meta-analysis indicated that OR of overall effective rate was 3.61 [95% CI（2.93,4.44） ].Conclusion：The Meta analysis results indicate the-preparation have improved cerebral infarction patients all hemorrheology and increased blood flow to the brain microcirculation.Because of the cerebral infarction randomized controlled trials,the methodological quality low potential clinical heterogeneity and sexual bias,and to study the influence of such factors as evaluation and reduce the reliability of the above conclusions,this system evaluation is not sure to prove the preparation of cerebral infarction safety and efficacy.